At­las-backed neu­rol­o­gy play­er Arku­da reemerges from the grind­stone with a lead pro­gran­ulin drug ap­proach­ing the clin­ic

In the bustling biotech space, a cou­ple years can feel like an eter­ni­ty — but for an At­las Ven­ture-backed neu­rol­o­gy play­er with a nov­el spin on R&D, a few qui­et years aren’t the worst thing in the world.

Arku­da Ther­a­peu­tics closed a $64 mil­lion Se­ries B round co-led by Cor­morant As­set Man­age­ment and Piv­otal bioVen­ture Part­ners with a lead mod­u­la­tor tar­get­ing fron­totem­po­ral de­men­tia (FTD) edg­ing clos­er to the clin­ic, the com­pa­ny said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER